Three new findings are reviewed that help to understand the mechanisms of action of antirheumatic Au(I) drugs, such as disodium aurothiomalate (Na2Au(I)TM): (i) We found that Na2Au(I)TM selectively inhibits T cell receptor (TCR)-mediated antigen recognition by murine CD4 + T cell hybridomas specific for antigenic peptides containing at least two cysteine residues. Presumably, Au(I) acts as a chelating agent forming linear complexes (Cys-Au(I)-Cys) which prevent correct antigenprocessing and/or peptide recognition by the TCR. (ii) We were able to show that Au(I) is oxidized to Au(lll) in phagocytic cells, such as macrophages. Because Au(lll) is re-reduced to Au(I) this may introduce an Au(I)/Au(lll) redox system into phagocytes which scavenges reactive oxygen species, such as OCI" and inactivates lysosomal enzymes. (iii) Pretreatment with Au(lll) of a model protein antigen, bovine ribonuclease A (RNase A), induced novel antigenic determinants recognized by CD4 + T lymphocytes. Analysis of the fine specificity of these 'Au(lll)-specific' T cells revealed that they react to RNase peptides that are not presented to T cells when the native protein, i.e., not treated with Au(lll), is used as antigen. The T cell recognition of these cryptic peptides did not require the presence of gold. This finding has important implications for understanding the pathogenesis of allergic and autoimmune responses induced by Au(I) drugs. Taken together, our findings indicate that Au(I) and Au(lll) each exert specific effects on several distinct components of macrophages and the subsequent activation of T cells; these effects may explain both the desired anti-inflammatory and the adverse effects of antirheumatic gold drugs.
INTRODUCTION
The Antirheumatic Drug Gold, A Coin with Two Faces: A U(I) andA U(III).
Desired and Undesired Effects on the lmmune System All antirheumatic gold drugs, such as disodium aurothiomalate (Na2Au(I)TM) contain gold in the oxidation state +1. The mechanism of action of gold drugs is unknown, but they are effective in the treatment of rheumatoid arthritis. With respect to both their therapeutic and adverse effects gold drugs have been termed 'slowacting' because there is a lag period of several weeks to months before they become effective (1, 2). Eventually adverse immune reactions necessitate discontinuation of gold therapy in up to one-third of patients (3) (4) (5) . The immunopathologic alterations developing under gold therapy (6) are summarized in Table 1 . Although antirheumatic gold drugs have been successfully used for almost six decades, the mechanism of action underlying their beneficial and their adverse effects are still largely unknown. This represents a challenge to both immunopharmacology and immunotoxicology. Here, we shall review recent results from our laboratory that help to understand the mechanism of action of these compounds. (13) (14) (15) and that gold accumulates in kidney, liver, and spleen (16) (17) (18) (19) (20) . Using morphological techniques for the examination of these organs, gold was found to be stored preferentially in lysosomes or lysosome-like organelles of phagocytic cells (7-10). Ghadially (7), who used electron X-ray analysis to describe such lysosomal bodies containing gold, introduced the term 'aurosomes' for these organelles. Other investigators who showed the uptake and storage of gold in phagocytes used electron microscopy and autometallography, respectively (10, 21, 22) . In all these studies, however, gold concentrations were only determined after cessation of treatment, never during ongoing treatment. Moreover, if the kinetics of gold in the body were studied at all, these measurements were confined to but a few organs and points in time.
As no systematic pharmacokinetic studies had been performed in animals or men to determine gold tissue concentrations under chronic treatment, our group performed such a study in mice using chronic treatment with Na2Au(I)TM and atomic absorption spectrometry (AAS) (12 (6, (23) (24) (25) (34, 35) . Severals authors (7, 9, 18, 21, 36) have described the accumulation and storage of gold in lysosomes or lysosome-like cellular bodies of macrophages, and it is conceivable that these organelles are the primary anatomical site of the pharmacologic and toxicologic action of gold drugs at the subcellular level.
Au(I) INTERFERES WITH ANTIGEN-PROCESSING IN MACROPHAGES AND THE PRESENTATION OF IMMUNOGENIC PEPTIDES CONTAINING TWO OR MORE CYSTEINE RESIDUES
A number of findings suggest that the pharmacological mechanism of Au(I) drugs directly or indirectly involves an effect on T lymphocytes. Na2Au(I)TM was found to inhibit the proliferation of human T cells to IL-2 in vitro at concentrations higher than 15 pM (27). Proliferation of human T cells induced by stimulation with phorbol myristate acetate (PMA) and anti-CD3 monoclonal antibody (mAb) was inhibited by Na2Au(I)TM concentrations higher than 30 IM (37). Na2Au(I)TM inhibited protein kinase C (PKC) activity, but had no effect on the generation of inositol 1,4,5 trisphosphate (IP3) (37 (6) , a perplexing result was obtained.
The gold(I) drug Na2Au(I)TM, although a potent inducer of adverse immune reactions upon weekly intramuscular injections, failed to elicit the expected T cell reaction in the direct popliteal lymph node assay (PLNA). By contrast, equimolar amounts of Au(lll) salts readily induced a T cell-dependent PLN reaction. The PLNA is an in vivo test system for measuring specific T cell reactions toward chemicals of low molecular weight (6, (51) (52) (53) .
To explain this discrepancy the hypothesis has been proposed that in vivo the Au(I) of the slow-acting drug Na2Au(I)TM is gradually oxidized to Au(lll), and that it is the latter which elicits T cell sensitization and thus initiates the GVH-like side-effects. This was experimentally tested by Schuhmann et al. (6) On the basis of their findings obtained with the adoptive transfer PLNA, Schumann et al. (6) concluded that the adverse immune effects of Au(I) salts are in fact caused by Au(lll) which must be generated in vivo through oxidation of Au(I). In both animals and humans, gold is known to be accumulated and stored in the lysosomes of monocytes and macrophages (7, 54, 55) . Here, Au(I) might be oxidized to Au(lll) by reactive oxygen species, such as HOCI (Fig. 1) . In fact, in a cell-free system in vitro, which contained the HOCI-generating factors H202, CI', and myeloperoxidase (MPO), Au(lll) was generated from Na2Au(I)TM (56; and 
THE BIOOXIDATION OF Au(I) TO Au(lll) TAKES PLACE IN PHAGOCYTIC CELLS
Recently our group was able to provide direct experimental evidence for the concept (Fig. 1) that biooxidation of Au(I) to Au(lll) takes place in phagocytic cells, such as monocytes and macrophages. T cells of mice were primed to Au(lll) either by weekly intramuscular injections of Au(I) in the form of Na2Au(I)TM, or by three subcutaneous injections of HAu(III)CI 4. Using the adoptive transfer PLNA, the transferred T cells of these animals were found to react in an anamnestic fashion not only to the Au(lll) salt, but also to homogenized macrophages pretreated with Na2Au(I)TM. The macrophages used were either activated syngeneic macrophages that had been incubated with Na2Au(I)TM in vitro or peritoneal cells obtained from syngeneic donors that had received weekly intramuscular injections of Na2Au(I)TM for 12 weeks (C. Goebel, M. Kubicka-Muranyi, T. Tonn, J. Gonzalez, and E. Gleichmann, manuscript submitted).
In humans who had been treated with Au(I) drugs for rheumatoid arthritis and had subsequently developed dermatitits, anamnestic T cells responses to Au(lll) were also observed (39, 60, 61; and T. Tonn, unpublished results). Verwilghen et al. (61) tested peripheral blood lymphocytes of 17 patients with acute gold dermatitis in the lymphocyte transformation test in vitro, and found that the cells of 13 of them reacted to Au(lll), but not to Na2Au(I)TM or other heavy metal salts.
While the results of Verwilghen et al. (61) clearly reflect the differential immunogenicity of Au(I) and Au(lll) salts and thus confirm in humans the findings obtained in mice (6) , the picture is not quite as clearcut in all investigations. In a few patients a positive reaction to both Au(lll) and Au(I) was observed (T. Tonn, unpublished results). Here, it can be argued that the putative reaction to Au(i) was in fact directed towards Au(lll) that was generated by monocytes through oxidation of Au(I) during the 1-week culture period. This explanation, however, can only be applied with difficulty to the findings of Romagnoli et al. (39) . They found that two T cell clones obtained from the same patient reacted to both Au(I) and Au(lll) even when the antigen-presenting cells (Epstein-Barr virus-transformed autologous B cells) were glutaraldehyde-fixed. It is generally agreed that glutaraldehyde fixation inactivates enzyme activities in cells (62, 63) ; if true, this would also pertain to the enzymes involved in the oxidation of Au(I) to Au(lll). A possible explanation for the inability of the two cell clones to distinguish between Au(I) and Au(lll) could be that the Au(I) salt induces a conformational change of MHC class II molecules (64). Conceivably, the two T cell clones studied by Romagnoli et al. (39) were specific for class II molecules thus changed. Because Au(lll)is rapidly reduced to Au(I) by protein, it may have caused identical reactions as Au(I) in this particular case. Immunization of C57BL/6 mice with native RNase A leads to activation of T cells that are specific for peptide 74-88. When mice were immunized with RNase A that had been oxidized with Au(lll) (58), additional T cell specificities were found. T cell clones that reacted to RNase/Au(lll) but not to native RNase, were found to be specific for peptide 7-21 or peptide 94-108. Au(lll) addition was not required for the recognition of the peptides but alteration of the protein by Au(lll) was necessary for efficient cleavage of these peptides from the protein during antigen-processing.
Au(lll) INDUCES THE PRESENTATION OF CRYPTIC PEPTIDES
As the self proteins altered by Au(lll) have not yet been identified, we used bovine RNase A as a model antigen and oxidized it by pretreatment with Au(lll) at pH 2, as described by Isab and Sadler (58). Mice were immunized against RNase/Au(lll), and CD4 + T cell hybridomas specifically recognizing RNase/Au(lll), but not native RNase, were established (P. Griem, K. Beyer, and E. Gleichmann, manuscript submitted). By using a set of overlapping peptides of bovine RNase A, each 15 amino acids long, we were able to identify two peptides recognized by these T cell hybridomas (Fig. 2) Arguments for phagocytic cells as potential sites for the generation of reactive drug metabolites (66) were summarized above. Regarding the actual immunogenicity of drug metabolites thus generated, the findings obtained with Au(I)/Au(lll) were the first to give experimental support to this important concept. Au(lll), however, is a somewhat unusual intermediate whose generation in the body has been demonstrated only in the indirect fashion outlined above. In contrast, the production by phagocytes of reactive metabolites of procainamide (66-69) is generally accepted.
Therefore, we recently started to perform similar experiments with procainamide and its reactive metabolites using the same experimental approach as with Au(I)/Au(lll).
POSSIBLE IMPLICATIONS OF THE BIOOXIDATION OF Au(I) TO Au(lll)
Generation of the highly reactive intermediate Au(lll) could also be relevant with respect to the unknown pharmacological mechanism of action of Au(I) drugs. Three anti-inflammatory mechanisms of Au(lll) may be envisaged (Fig. 3) . Firstly, the generation in phagocytic cells of Au(lll) from Au(I) scavenges reactive oxygen species. Secondly, as already mentioned, Au(lll) is a highly reactive chemical that irreversibly denatures protein (57). The candidate proteins to be denatured by Au(lll) are those nearest to the site of oxidation of Au(I) to Au(lll) . Presumably these are the proteins located in the phago-lysosomes of phagocytic cells (60, 65) , such as iysosomal enzymes, which are known to enhance inflammation when released from cells. Thirdly, Au(lll) may interfere with those lysosomal enzymes involved in antigen-processing or may directly alter MHC molecules. Both mechanisms could result in reduced production or presentation of arthritogenic (self) peptides. These anti-inflammatory effects of gold should be enhanced and prolonged by the fact that Au(lll) is very short-lived in the presence of protein because it rapidly oxidizes protein and is re-reduced to Au(I) (20, 58) . In fact, as pointed out by C.F. Shaw III (personal communication, 1991) , on the basis of the findings of Schuhmann et al. (6) gold therapy may introduce a Au(I)/Au(lll) redox system into phagocytic cells (Fig. 3) . If this view is correct, the three anti-inflammatory actions of Au(I)/Au(lll) described above would be effective over a prolonged period of time.
